• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

利用整合的个体和群组转录组网络分析深入了解胰腺导管腺癌 (PDAC) 患者的长期生存异质性。

Deeper insights into long-term survival heterogeneity of pancreatic ductal adenocarcinoma (PDAC) patients using integrative individual- and group-level transcriptome network analyses.

机构信息

GIGA-R Centre, BIO3 - Medical Genomics, University of Liège, Avenue de L'Hôpital, 11, 4000, Liège, Belgium.

Laboratory of Human Genetics, GIGA Research, University Hospital (CHU), Liège, Belgium.

出版信息

Sci Rep. 2022 Jun 30;12(1):11027. doi: 10.1038/s41598-022-14592-1.

DOI:10.1038/s41598-022-14592-1
PMID:35773268
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9247075/
Abstract

Pancreatic ductal adenocarcinoma (PDAC) is categorized as the leading cause of cancer mortality worldwide. However, its predictive markers for long-term survival are not well known. It is interesting to delineate individual-specific perturbed genes when comparing long-term (LT) and short-term (ST) PDAC survivors and integrate individual- and group-based transcriptome profiling. Using a discovery cohort of 19 PDAC patients from CHU-Liège (Belgium), we first performed differential gene expression analysis comparing LT to ST survivor. Second, we adopted systems biology approaches to obtain clinically relevant gene modules. Third, we created individual-specific perturbation profiles. Furthermore, we used Degree-Aware disease gene prioritizing (DADA) method to develop PDAC disease modules; Network-based Integration of Multi-omics Data (NetICS) to integrate group-based and individual-specific perturbed genes in relation to PDAC LT survival. We identified 173 differentially expressed genes (DEGs) in ST and LT survivors and five modules (including 38 DEGs) showing associations to clinical traits. Validation of DEGs in the molecular lab suggested a role of REG4 and TSPAN8 in PDAC survival. Via NetICS and DADA, we identified various known oncogenes such as CUL1 and TGFB1. Our proposed analytic workflow shows the advantages of combining clinical and omics data as well as individual- and group-level transcriptome profiling.

摘要

胰腺导管腺癌 (PDAC) 是全球癌症死亡的主要原因。然而,其长期生存的预测标志物尚不清楚。当比较长期 (LT) 和短期 (ST) PDAC 幸存者并整合个体和基于群体的转录组谱时,描绘个体特异性失调基因是很有趣的。我们使用来自比利时 CHU-Liège 的 19 名 PDAC 患者的发现队列,首先比较 LT 与 ST 幸存者进行差异基因表达分析。其次,我们采用系统生物学方法获得具有临床相关性的基因模块。第三,我们创建个体特异性扰动谱。此外,我们使用 Degree-Aware disease gene prioritizing (DADA) 方法来开发 PDAC 疾病模块;Network-based Integration of Multi-omics Data (NetICS) 将基于群体和个体特异性的扰动基因与 PDAC LT 生存相关联。我们在 ST 和 LT 幸存者中鉴定了 173 个差异表达基因 (DEGs) 和五个与临床特征相关的模块 (包括 38 个 DEGs)。在分子实验室验证 DEGs 表明 REG4 和 TSPAN8 在 PDAC 生存中起作用。通过 NetICS 和 DADA,我们鉴定了各种已知的癌基因,如 CUL1 和 TGFB1。我们提出的分析工作流程显示了结合临床和组学数据以及个体和基于群体的转录组谱分析的优势。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b4a1/9247075/62744cb62f87/41598_2022_14592_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b4a1/9247075/2e4b5a2007d2/41598_2022_14592_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b4a1/9247075/50f8d74971b9/41598_2022_14592_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b4a1/9247075/37109f558f78/41598_2022_14592_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b4a1/9247075/e3354e0afc4c/41598_2022_14592_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b4a1/9247075/1f042a083ef3/41598_2022_14592_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b4a1/9247075/3a4a75e04391/41598_2022_14592_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b4a1/9247075/62744cb62f87/41598_2022_14592_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b4a1/9247075/2e4b5a2007d2/41598_2022_14592_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b4a1/9247075/50f8d74971b9/41598_2022_14592_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b4a1/9247075/37109f558f78/41598_2022_14592_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b4a1/9247075/e3354e0afc4c/41598_2022_14592_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b4a1/9247075/1f042a083ef3/41598_2022_14592_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b4a1/9247075/3a4a75e04391/41598_2022_14592_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b4a1/9247075/62744cb62f87/41598_2022_14592_Fig7_HTML.jpg

相似文献

1
Deeper insights into long-term survival heterogeneity of pancreatic ductal adenocarcinoma (PDAC) patients using integrative individual- and group-level transcriptome network analyses.利用整合的个体和群组转录组网络分析深入了解胰腺导管腺癌 (PDAC) 患者的长期生存异质性。
Sci Rep. 2022 Jun 30;12(1):11027. doi: 10.1038/s41598-022-14592-1.
2
Gene expression profiling of 1200 pancreatic ductal adenocarcinoma reveals novel subtypes.对 1200 例胰腺导管腺癌的基因表达谱分析揭示了新的亚型。
BMC Cancer. 2018 May 29;18(1):603. doi: 10.1186/s12885-018-4546-8.
3
Single-cell transcriptome reveals the heterogeneity of malignant ductal cells and the prognostic value of REG4 and SPINK1 in primary pancreatic ductal adenocarcinoma.单细胞转录组揭示了原发性胰腺导管腺癌中恶性导管细胞的异质性和 REG4 和 SPINK1 的预后价值。
PeerJ. 2024 May 28;12:e17350. doi: 10.7717/peerj.17350. eCollection 2024.
4
Identification of novel genes associated with a poor prognosis in pancreatic ductal adenocarcinoma via a bioinformatics analysis.通过生物信息学分析鉴定与胰腺导管腺癌预后不良相关的新基因。
Biosci Rep. 2019 Aug 2;39(8). doi: 10.1042/BSR20190625. Print 2019 Aug 30.
5
Weighted gene co-expression network analysis reveals key genes involved in pancreatic ductal adenocarcinoma development.加权基因共表达网络分析揭示了参与胰腺导管腺癌发展的关键基因。
Cell Oncol (Dordr). 2016 Aug;39(4):379-88. doi: 10.1007/s13402-016-0283-7. Epub 2016 May 30.
6
SCNrank: spectral clustering for network-based ranking to reveal potential drug targets and its application in pancreatic ductal adenocarcinoma.SCNrank:基于网络的排序的谱聚类揭示潜在的药物靶点及其在胰腺导管腺癌中的应用。
BMC Med Genomics. 2020 Apr 3;13(Suppl 5):50. doi: 10.1186/s12920-020-0681-6.
7
Identification of potential core genes at single-cell level contributing to pathogenesis of pancreatic ductal adenocarcinoma through bioinformatics analysis.通过生物信息学分析鉴定单细胞水平促进胰腺导管腺癌发病机制的潜在核心基因。
Cancer Biomark. 2022;34(1):1-12. doi: 10.3233/CBM-210271.
8
A Network-Based Approach for Identification of Subtype-Specific Master Regulators in Pancreatic Ductal Adenocarcinoma.基于网络的方法鉴定胰腺导管腺癌亚型特异性主调控因子
Genes (Basel). 2020 Feb 1;11(2):155. doi: 10.3390/genes11020155.
9
Identification of key regulators of pancreatic cancer progression through multidimensional systems-level analysis.通过多维系统水平分析鉴定胰腺癌进展的关键调节因子。
Genome Med. 2016 May 3;8(1):38. doi: 10.1186/s13073-016-0282-3.
10
Identification of differentially expressed genes in pancreatic ductal adenocarcinoma and normal pancreatic tissues based on microarray datasets.基于基因芯片数据集鉴定胰腺导管腺癌与正常胰腺组织中的差异表达基因。
Mol Med Rep. 2019 Aug;20(2):1901-1914. doi: 10.3892/mmr.2019.10414. Epub 2019 Jun 24.

引用本文的文献

1
From loneliness to depression: A longitudinal diagnostic study among Norwegian university students.从孤独到抑郁:挪威大学生的纵向诊断研究
Soc Psychiatry Psychiatr Epidemiol. 2025 Sep 17. doi: 10.1007/s00127-025-02989-y.
2
Novel Methodology for the Design of Personalized Cancer Vaccine Targeting Neoantigens: Application to Pancreatic Ductal Adenocarcinoma.针对新抗原设计个性化癌症疫苗的新方法:在胰腺导管腺癌中的应用
Diseases. 2024 Jul 11;12(7):149. doi: 10.3390/diseases12070149.
3
Prediction of response to promising first-line chemotherapy in ovarian cancer patients with residual peritoneal tumors: practical biomarkers and robust multiplex models.

本文引用的文献

1
From state-of-the-art treatments to novel therapies for advanced-stage pancreatic cancer.从最先进的治疗方法到晚期胰腺癌的新型疗法。
Nat Rev Clin Oncol. 2020 Feb;17(2):108-123. doi: 10.1038/s41571-019-0281-6. Epub 2019 Nov 8.
2
Programmed Cell Death Ligand-1 (PD-L1) and CD8 Expression Profiling Identify an Immunologic Subtype of Pancreatic Ductal Adenocarcinomas with Favorable Survival.程序性细胞死亡配体-1(PD-L1)和 CD8 表达谱分析确定具有良好生存预后的胰腺导管腺癌的免疫亚型。
Cancer Immunol Res. 2019 Jun;7(6):886-895. doi: 10.1158/2326-6066.CIR-18-0822. Epub 2019 May 1.
3
Therapeutic efficacy of anti-MMP9 antibody in combination with nab-paclitaxel-based chemotherapy in pre-clinical models of pancreatic cancer.
预测有残留腹膜肿瘤的卵巢癌患者对一线有前途化疗的反应:实用的生物标志物和稳健的多重模型。
Int J Clin Oncol. 2024 Sep;29(9):1334-1346. doi: 10.1007/s10147-024-02552-w. Epub 2024 May 20.
抗 MMP9 抗体联合 nab-紫杉醇化疗在胰腺癌临床前模型中的疗效。
J Cell Mol Med. 2019 Jun;23(6):3878-3887. doi: 10.1111/jcmm.14242. Epub 2019 Apr 2.
4
Immunological targets for cancer therapy: new recognition.癌症治疗的免疫靶点:新认知。
Immunotargets Ther. 2018 Nov 21;7:83-85. doi: 10.2147/ITT.S191821. eCollection 2018.
5
Suppression of stromal-derived Dickkopf-3 (DKK3) inhibits tumor progression and prolongs survival in pancreatic ductal adenocarcinoma.抑制基质衍生的 Dickkopf-3(DKK3)可抑制胰腺导管腺癌的肿瘤进展并延长生存期。
Sci Transl Med. 2018 Oct 24;10(464). doi: 10.1126/scitranslmed.aat3487.
6
Integration of Molecular Interactome and Targeted Interaction Analysis to Identify a COPD Disease Network Module.整合分子互作组和靶向互作分析以识别 COPD 疾病网络模块。
Sci Rep. 2018 Sep 27;8(1):14439. doi: 10.1038/s41598-018-32173-z.
7
Stratification of Pancreatic Ductal Adenocarcinomas Based on Tumor and Microenvironment Features.基于肿瘤和微环境特征的胰腺导管腺癌分层。
Gastroenterology. 2018 Dec;155(6):1999-2013.e3. doi: 10.1053/j.gastro.2018.08.033. Epub 2018 Aug 27.
8
Transcriptome sequencing identifies key pathways and genes involved in gastric adenocarcinoma.转录组测序鉴定胃腺癌相关的关键途径和基因。
Mol Med Rep. 2018 Oct;18(4):3673-3682. doi: 10.3892/mmr.2018.9370. Epub 2018 Aug 9.
9
Pancreatic cancer survival analysis defines a signature that predicts outcome.胰腺癌生存分析定义了一个预测结果的特征。
PLoS One. 2018 Aug 9;13(8):e0201751. doi: 10.1371/journal.pone.0201751. eCollection 2018.
10
Gene expression profiling of 1200 pancreatic ductal adenocarcinoma reveals novel subtypes.对 1200 例胰腺导管腺癌的基因表达谱分析揭示了新的亚型。
BMC Cancer. 2018 May 29;18(1):603. doi: 10.1186/s12885-018-4546-8.